Surgery Partners (SGRY) Q4 2025 earnings review
Growth Hits a Wall as Margins Compress and Guidance Disappoints
Surgery Partners' double-digit growth story abruptly stalled in Q4. Total revenue barely edged up 2.4%, while Adjusted EBITDA actually shrank 4.2% YoY. More concerning: total surgical cases reversed into negative territory (-2.1%). Management cited 'significant and unanticipated headwinds,' including provider taxes and tariff pressures. The company's 2026 guidance is a cold shower, projecting virtually flat Adjusted EBITDA. To cushion the blow, the Board authorized a $200M share repurchase program, though leveraging the balance sheet further to buy back stock raises eyebrows.
🐂 Bull Case
Total joint procedures grew 15% YoY in Q4, driving the same-facility rate up 2.1%. The migration of complex, high-margin musculoskeletal procedures to the outpatient setting continues to work.
The new $200M share repurchase program provides immediate support for the stock, signaling that management believes shares are undervalued despite the near-term operational noise.
🐻 Bear Case
Initial 2026 Adjusted EBITDA guidance of $530M+ is basically flat compared to 2025's $526M. Margin compression has effectively neutralized top-line growth.
Total surgical cases reversed to a 2.1% decline in Q4. While portfolio optimization plays a role, underlying same-facility case growth decelerated sharply to just 1.3%.
⚖️ Verdict: 🔴
Bearish. The abrupt deceleration in top-line growth, coupled with margin compression and uninspiring 2026 guidance, fundamentally damages the company's historical compounding growth narrative.
Key Themes
Total Volume Trend is Reversing
A massive red flag emerged in Q4: total surgical cases dropped 2.1% YoY to 170,468. While same-facility cases managed a meager 1.3% increase, this represents a severe deceleration from the 5.1% same-facility growth seen a year prior. The company's core engine of organic volume expansion is sputtering.
Macro Headwinds: Tariffs and Medicaid Pressures
In prior quarters, management explicitly dismissed tariff risks. Now, the 2026 outlook presentation specifically bridges a $12M EBITDA penalty directly attributed to macro factors: $8M from Provider Tax & Medicaid Pressures and $4M from Incremental Tariff Pressures. This contradicts previous confident narratives about supply chain immunity.
High-Acuity Mix and Robotics
The brightest spot remains the intentional shift toward complex cases. Musculoskeletal procedures hit 88k+ in Q4, and Total Joint procedures grew an impressive 15% YoY. This is supported by specific technology investments, with the company adding 6 surgical robots in 2025, bringing the total fleet to 74. This drives revenue per case higher (+2.1% same-facility in Q4).
Margin Compression is Accelerating
Adjusted EBITDA margins compressed to 17.7% in Q4 2025, down from 18.9% in Q4 2024. Full-year margins also slipped to 15.9% (vs 16.3% in 2024). This is the exact opposite of the 'margin expansion via operational efficiency' algorithm management has promised investors for the last year.
Strategic Portfolio Optimization
Management continues to emphasize 'effective portfolio optimization.' Given the drop in total cases versus same-store cases, Surgery Partners is clearly pruning underperforming or non-core assets. While this shrinks the total revenue base, it is intended to eventually improve cash flow conversion and reduce overall leverage.
Other KPIs
Decelerating. Cash from operations fell from $300.1M in FY24 to $274.3M in FY25. This deterioration in cash generation makes the decision to launch a $200M share repurchase program highly aggressive, especially given the company's debt load.
Reversing. Leverage climbed significantly from 3.7x at the end of 2024 to 4.3x at the end of 2025. Unadjusted balance sheet leverage is even higher at 4.9x. The promised deleveraging trajectory has been completely derailed.
Decelerating compared to the $34.0M seen in Q4 2024, but these 'add-backs' remain persistently high and drag on actual GAAP profitability. Full-year add-backs for M&A and integration totaled $73.9M.
Guidance
Stable/Decelerating. This target represents a dismal 0.7% growth over 2025's $526.2M. The company expects Q1 to represent only ~19% of this total ($100.7M), implying a very back-half weighted year heavily reliant on 'tightening execution' rather than current momentum.
Decelerating. The midpoint of $3.40B implies just 2.7% YoY growth. This is a massive step down from the 13.5% growth delivered in 2024 and the 6.2% delivered in 2025, reflecting both slower M&A cadence and portfolio optimization.
Decelerating. Dropping from 4.9% same-facility growth in 2025 and 8.0% in 2024. The core organic engine is guiding significantly below historical norms.
Key Questions
Divergence in Capital Allocation
With leverage climbing to 4.3x and operating cash flow declining YoY, what is the strategic rationale for authorizing a $200M share repurchase program instead of aggressively paying down floating-rate debt?
Tariff and Supply Chain Reality
Earlier in the year, management explicitly stated there was 'no material exposure' to tariffs due to GPO contracts. The 2026 bridge now includes $4M in tariff pressure. What broke in the supply chain visibility to cause this reversal?
Volume Contraction Mechanics
Total surgical cases declined 2.1% in Q4. How much of this was strictly due to strategic divestitures versus organic attrition or physician turnover?
Bridge to 2026 Guidance
Given the 2026 guide implies virtually zero Adjusted EBITDA growth at the low end, is the company pausing its historical $200M/year M&A algorithm, or are base business margins eroding fast enough to offset new acquisitions completely?